HANGZHOU, China, July 15, 2025 – WinHealth Pharma proudly supported the "Relay of Life – Pediatric Progeria Treatment Charity Program", with the donation ceremony for its fifth batch of medicines held at the Binjiang Campus of Children's Hospital Zhejiang University School of Medicine. Among those in attendance were Professor Jianhua Mao, Vice President of Children's Hospital Zhejiang University School of Medicine; Hong Wu, Chair of the Zhejiang Women and Children’s Foundation; Chenxia He, Executive Deputy Secretary‑General of the Zhejiang Women and Children’s Foundation; and Qi Wang, General Manager of Zhejiang Medical Technology Development Co., Ltd., a subsidiary of Hong Kong WinHealth Pharma Group (WinHealth Pharma).
Group photo at the donation ceremony
WinHealth Pharma delivered the fifth batch, 52 vials of progeria medicine valued at RMB 9,647,600, to Children's Hospital Zhejiang University School of Medicine. As the program’s charitable service partner, the company managed the end‑to‑end supply chain, from customs clearance to on‑site hospital delivery. Leveraging its specialized expertise and robust logistics network, the company ensures these life‑saving therapies reach patients promptly and securely, facilitating timely treatment and safeguarding precious lives.
Rising to the Challenge and Safeguarding Lives
Throughout the import and distribution of this donation, the WinHealth Pharma team demonstrated unwavering commitment and professionalism, overcoming multiple hurdles through proactive coordination across stakeholders to ensure swift delivery to patients. The supply chain team immediately partnered with regulatory authorities and clinical teams to jointly and efficiently secure critical approval changes. Faced with stringent timelines, the team expedited import documentation, port inspections and hospital delivery—completing the entire clearance‑to‑delivery process in just two days. The rapid deployment ensured the life‑saving therapy reached patients without delay, securing invaluable treatment time. This swift execution of the fifth batch underscores WinHealth Pharma’s steadfast support to rare‑disease patients, with every step reflecting compassionate teamwork and operational excellence.
A young patient walking with family support
Jack Wang,Chairman of Hong Kong WinHealth Pharma Group
"Putting patients first has always been our guiding principle. By introducing innovative therapies and treatment solutions, we address evolving clinical needs and continuously enhance patients’ quality of life. The successful completion of this program not only reflects the strong trust and recognition we’ve earned across society, but also reinforces our long‑term dedication and sense of responsibility in supporting charitable healthcare initiatives. Going forward, we will deepen collaboration with all stakeholders, maintain unwavering focus on critical patient priorities, and continue to uphold our corporate social responsibility—delivering sustainable, lasting value for patients and communities.”
Oliver Hao,Executive Director and Co-CEO of Hong Kong WinHealth Pharma Group
“We are proud to support the Relay of Life program and deeply grateful for the trust placed in us by our partners and stakeholders. From global coordination and regulatory authorizations to import clearance and final‑mile delivery, our team has exemplified professional, rigorous and results‑driven execution—ensuring this life‑saving therapy reach patients in urgent need without delay. WinHealth Pharma remains resolute in its commitment to patients, partners and employees, continually enhancing our operational excellence and service standards to drive meaningful impact and protect lives.”
Relay Continues, Mission Unchanged
To date, with WinHealth Pharma’s support, the Relay of Life – Pediatric Progeria Treatment Charity Program has delivered progeria medicines valued at RMB 77,253,200, enabling 14 children to maintain uninterrupted treatment. Before therapy, these children faced severe complications — extreme underweight, skeletal deformities and, in the most advanced cases, loss of independent mobility. Access to these life‑saving medicines has significantly alleviated their conditions and restored hope to both patients and their families. Since the program’s launch in 2022, five batches have been dispatched, providing sustained access to care for children across multiple regions in China. Beyond serving as the program’s logistics partner, WinHealth Pharma has also acted as project coordinator, policy interpreter and compliance facilitator — tirelessly overcoming barriers at every pivotal stage to ensure patients’ timely access to treatment.
Moving forward, WinHealth Pharma will remain committed to patients’ evolving treatment needs, further enhancing access to life‑saving therapies, and collaborating with industry partners to accelerate the introduction and commercialization of innovative therapies and service models. We are confident that, with sustained support from government bodies and sectors of society, public awareness of rare diseases and patient access to medicines will be further strengthened—bringing hope to more patients.
Acknowledgements
We would like to thank the following for their invaluable support and guidance:
- Zhihong Liu, Academician of the Chinese Academy of Engineering; Director, National Clinical Research Center for Kidney Diseases, General Hospital of Eastern Theater Command; Dean, Zhejiang University School of Medicine
- Zhejiang Medical Products Administration
- Health Commission of Zhejiang Province
- Children’s Hospital, Zhejiang University School of Medicine
- Chinese Organization for Rare Disorders
- Hangzhou Market Supervision Administration
- Zhejiang Women and Children’s Foundation
- Rare Disease Society of the Zhejiang Medical Association
- Progeria Research Foundation (PRF)
- Sentynl Therapeutics, Inc.
- Clinigen Healthcare Ltd.
- Qianjiang Customs Comprehensive Business Division III
- Qianjiang Customs Xiaoshan Hangzhou Comprehensive Bonded Zone
About WinHealth Pharma
Founded in 2006, WinHealth Pharma is a Hong Kong-headquartered biopharmaceutical company with a comprehensive, end-to-end value chain. The company focuses on three core areas: proprietary pharmaceutical products, CSO business, and specialty care, with a strong commitment to the development and commercialization of cutting-edge medicines. Guided by a patient-first philosophy, we are dedicated to delivering breakthrough therapies and innovative healthcare solutions to patients with cardio-renal diseases, hematologic cancers, gastrointestinal diseases, respiratory and infectious diseases, rare diseases, and other unmet medical needs. Our commitment is to improve patients’ lives through transformative treatments. With a well-established presence in China, WinHealth Pharma is actively expanding across Asia and other international markets, building a comprehensive healthcare ecosystem, driving innovation, and addressing the evolving treatment needs of patients. For more information, please visit www.winhealth.hk.